Biorestorative Therapies, Inc. (BRTX) Stock Price & Analysis
Biorestorative Therapies, Inc. (BRTX) rose 8.95% to USD 0.39 as of June 10, 2026 at 11:21 UTC, according to Nexqual real-time market data.
BRTX last closed at USD 0.36; the session ranged USD 0.36–0.41 on volume of 998,638 shares. Market capitalization is $10.05M, with a 52-week range of USD 0.16–2.05 (NCM). Source: Nexqual, June 10, 2026 at 11:21 UTC.
Key Statistics (as of June 10, 2026 at 11:21 UTC)
| Price | USD 0.39 |
|---|---|
| Change | ▲ 8.95% (up) |
| Previous Close | USD 0.36 |
| Open | USD 0.36 |
| Day Range | USD 0.36 – 0.41 |
| 52-Week Range | USD 0.16 – 2.05 |
| Volume | 998,638 shares |
| Market Cap | $10.05M |
| Exchange | NCM |
Technical Analysis (BRTX)
Nexqual's technical model rates BRTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 11:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.8 (neutral) |
| vs SMA50 | Above (USD 0.26) |
| MACD | 0.04 (positive) |
Analyst Ratings (BRTX)
Wall Street analysts rate BRTX "None" based on 2 analysts, with a mean price target of USD 8 (range USD 1–15), per Nexqual as of June 10, 2026 at 11:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 8 |
| High Target | USD 15 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (BRTX)
| EPS Estimate | USD -0.15 |
|---|---|
| Revenue Estimate | $335,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.32 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.38 ▲ beat |
| 2025-06-30 | USD -0.3 vs est -0.41 ▲ beat |
Source: Nexqual, June 10, 2026 at 11:21 UTC.
Financials & Fundamentals (BRTX)
| Total Revenue | $357,870 |
|---|---|
| Revenue Growth (YoY) | -7.30% |
| Gross Margin | +92.09% |
| Operating Margin | -14612.57% |
| Profit Margin | +0.00% |
| ROE | -241.14% |
| Current Ratio | 2.35 |
| Total Cash | $3.59M |
| Total Debt | $0 |
| Free Cash Flow | $-7.97M |
Source: Nexqual, June 10, 2026 at 11:21 UTC.
Financial Health Score (BRTX)
Nexqual rates Biorestorative Therapies, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:21 UTC.
| Growth | Critical — Revenue -10% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -241%, ROA -118.8% |
Ownership (BRTX)
| Insider Ownership | +12.13% |
|---|---|
| Institutional Ownership | +7.26% |
| Shares Outstanding | 25.48M |
| Float | 24.18M |
| Short % of Float | +26.25% |
Source: Nexqual, June 10, 2026 at 11:21 UTC.
Leadership (BRTX)
Biorestorative Therapies, Inc. is led by Lance Alstodt (age 54), Chairman of the Board, President & CEO, per Nexqual as of June 10, 2026 at 11:21 UTC.
| Chairman of the Board, President & CEO | Lance Alstodt (age 54) |
|---|---|
| Chief Financial Officer | Robert Eugene Kristal (age 57) |
| VP of Research & Development, Secretary and Director | Francisco J. Silva (age 50) |
Major Backers & Investors (BRTX)
Notable institutional backers of Biorestorative Therapies, Inc. include Citadel, Fidelity, UBS Group AG, according to Nexqual as of June 10, 2026 at 11:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 27.36% |
| Fidelity | 25.12% |
| UBS Group AG | 11.45% |
| Wealth Alliance, LLC | 4.59% |
| Osaic Holdings Inc. | 0.23% |
| Tower Research Capital LLC (TRC) | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 25.58% |
| Vanguard Group | 4.52% |
| State Street | 3.72% |
Source: Nexqual, June 10, 2026 at 11:21 UTC.
From Biorestorative Therapies, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
- The company develops programs related to the treatment of disc/spine disease and metabolic disorders.
- Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
- The company also operates a commercial biocosmeceutical platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CELZ | Creative Medical Technology Hol | USD 2.18 | ▲ 5.83% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
| BCDA | BioCardia, Inc. | USD 0.86 | ▼ 16.5% |
| CMND | Clearmind Medicine Inc. | USD 3.39 | ▼ 14.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:21 UTC. This page is informational and not investment advice.